Get started
Work

Testosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial

Year: 2024
Type: article
DOI: 10.1016/j.ijrobp.2024.07.1247
Authors: S. Moningi, P.L. Nguyen, D. Rathkopf, A. Zurita-Saavedra, D.E. Spratt, R.T. Dess, S. Liauw, R. Szmulewitz, D.J. Einstein, G. Bubley, J.B. Yu, Y. An, A.C. Wong, F.Y. Feng, R.R. Mckay, B.S. Rose, K.Y. Shin, M.E.A. Taplin, M.A. Kollmeier, K.E. Hoffman
Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Case Western Reserve University, University of Michigan, University of Chicago, Beth Israel Deaconess Medical Center, Yale University, University of California, San Francisco, University of California San Diego
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4402907395
FWCI:
Cites:
Cited by:
Related to: 10